Moreover, carbon-EBRT combined with anti-EGFR based EndoRT was studied using 131I-Cetuximab in a prototypic EGFR amplified A431 human squamous cell carcinoma xenograft model. This evidence concerns the gene EGFR and squamous cell carcinoma.